{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:57:04Z","timestamp":1773691024144,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.107925","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T01:58:38Z","timestamp":1754618318000},"page":"107925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial"],"prefix":"10.1016","volume":"157","author":[{"given":"Amir T.","family":"Fathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Vestin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107925_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2025.107925_bib2","unstructured":"SEER, Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML), 2025. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u3009. (Accessed 18 June 2025)."},{"issue":"3","key":"10.1016\/j.leukres.2025.107925_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473646","article-title":"Moving away from standard induction in newly diagnosed acute myeloid leukemia","volume":"45","author":"Okoniewski","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"7","key":"10.1016\/j.leukres.2025.107925_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.leukres.2025.107925_bib5","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.leukres.2025.107925_bib6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107925_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7012","article-title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine","volume":"41","author":"De Botton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107925_bib8","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/S2152-2650(23)00461-5","article-title":"POSTER: AML-446 time to resolution of myelosuppression and associated hospitalization in patients with newly-diagnosed acute myeloid leukemia (AML) treated with ivosidenib (IVO) + azacitidine (AZA) compared to placebo (PBO) + AZA","volume":"23","author":"Fathi","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2025.107925_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","article-title":"How we incorporate venetoclax in treatment regimens for acute myeloid leukemia","volume":"28","author":"Maiti","year":"2022","journal-title":"Cancer J."},{"issue":"6","key":"10.1016\/j.leukres.2025.107925_bib10","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1002\/cam4.5459","article-title":"Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy","volume":"12","author":"Laloi","year":"2023","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.leukres.2025.107925_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000912","article-title":"BCL2 inhibition: a new paradigm for the treatment of AML and beyond","volume":"7","author":"Wei","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.leukres.2025.107925_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/10428194.2024.2411436","article-title":"HMA\/VEN treatment modifications and associated outcomes in IDH-mutant AML","volume":"66","author":"Chin","year":"2025","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2025.107925_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH inhibitors in AML\u2014promise and pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2025.107925_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101195","article-title":"BCL-2 inhibition in haematological malignancies: clinical application and complications","volume":"65","author":"Fowler-Shorten","year":"2024","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.leukres.2025.107925_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.27515","article-title":"The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia","volume":"100","author":"DiNardo","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107925_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10238-021-00784-y","article-title":"Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis","volume":"23","author":"Qin","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.leukres.2025.107925_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyab170","article-title":"Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"52","author":"Yamamoto","year":"2022","journal-title":"Jpn J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:46:23Z","timestamp":1772808383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":17,"alternative-id":["S0145212625002851"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107925","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107925"}}